Safety and efficacy of Alternating mFOLFOX6 and FOLFIRI every 4cycles as First line Therapy in Advanced colorectal Cancer - Safety and efficacy of Alternating mFOLFOX6 and FOLFIRI every 4cycles as First line Therapy in Advanced colorectal Cancer(KSCC0701)

KSCC0 个研究点目标入组 47 人开始时间: 2008年8月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Administering antithrobotic drug within 7 days 2. Serious complications (renal failure or hepatic failure) 3. Serious drug hypersensitivity or a history of drug allergy 4. Peripheral neuropathy 5. Active concomitant malignancy 6. Active infections 7. High blood pressure and diabetic that cannot be controlled 8. symptomatic or asymptomatic but treated heart disease 9. interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema 10. histry of mental disturbances or cerebrovascular attach 11. Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer 12. Plerral effusion, peritoneal fluid and pericardial fluid 13. Symptomatic brain metastasis 14. Water solubility diarrhea, in case of the patient who has a colostomy, diarrhea impairs daily life activity 15. Need to treatment with atazanavir sulfate 16. under coutinuous steroid therapy 17. Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers 18. on other clinical trial 19. Other conditions not suitable for this study

发起方

KSCC